基于价值链分工的跨国生物医药企业在华布局模式  

Spatial Layout Pattern of International Biopharmaceutical Company in China Based on Value Chain Specialization

作　　者：李国平[1] 方晓晖[1] 

机构地区：[1]北京大学政府管理学院,北京100871

出　　处：《地域研究与开发》2016年第4期6-11,共6页Areal Research and Development

基　　金：国家自然科学基金项目(41171099);国家社会科学基金青年项目(15CJY055);教育部人文社会科学研究青年基金项目(14YJC790136)

摘　　要：从企业微观视角,深入分析了全球前30强生物医药企业的价值链不同环节在华布局特征及各环节间的空间分工模式。研究结果表明:(1)从整体上看,绝大多数企业集中在长三角、京津冀和珠三角三大区域,其中总部和研发中心都集中在北京和上海,制造基地则散布在三大经济区内。(2)从区域内部价值链分工看,长三角、京津冀的价值链分工体系较为成熟,珠三角仍处于利用其成本优势吸引制造基地布局阶段。(3)在华跨国生物医药企业内部"研发中心"与"制造基地"的分工存在跨区域、同区域跨城市和城市内部3种模式,在华投资的路径可以分为"先制造后总部研发"的制造先行模式和"先总部后制造研发"的总部先行模式。This study analyzes the spatial character of value chain of international biopharmaceutical companies in global top 30 and its spatial patterns. The main findings are as follows：（ 1） Most international companies mainly locate in Yangtze Delta Areas,Beijing-Tianjin-Hebei Region and Zhujiang Delta Areas. The headquarters and RD centers are concentrated in Beijing and Shanghai. Meanwhile the manufacturing bases are scattered across the three economic zones.（ 2） The division system of value-chain in Yangtze Delta Areas,Beijing-Tianjin-Hebei Region is much more developed than Zhujiang Delta Area＇s which still in the period of attracting investments on manufacturing bases.（ 3） There are three kinds of division of labor pattern between RD center and manufacturing base,namely cross-region,cross-cities in one region and inside city. There are two kinds of investment path,namely ＂headquarter and RD after manufacturing＂and ＂manufacturing and RD after headquarter＂.

关 键 词：价值链分工 生物医药 跨国企业 空间分工模式 

分 类 号：F061.5[经济管理—政治经济学]